PrintContact
 
  • Home
  • About Us
  • Sativex
  • R&D
  • Investors
  • Media
GW Pharmaceuticals
  • Cannabinoid Science
  • Therapeutic Areas
  • Product Pipeline
  • R&D Collaborations
  • Cultivation
  • GW Metabolic Research Laboratory
  • Cannabinoid Research Institute
  • Research Papers
  • R&D FAQs
  • Home
  • R&D

R&D

GW's research explores the potential therapeutic applications of cannabinoids and the endocannabinoid system across a wide range of disease areas.   

There are over 60 cannabinoid compounds identified to date. GW is researching a large number of cannabinoids, each of which has different effects and applications.

  • Oncology
  • Metabolic Syndrome
  • Psychiatric Disorders
  • Epilepsy
  • Inflammation

Information on cannabinoid compounds and the cannabinoid receptor system.

A summary of GW's product pipeline, including Sativex and other research targets.

 

GW collaborates with cannabinoid researchers at academic institutions in many countries.

GW places emphasis on plant breeding and cultivation techniques to support its research.

A dedicated metabolic research laboratory at the University of Buckingham.

 
 

© GW Pharmaceuticals 2009

  • Home
  • Sitemap
  • Accessibility
  • Disclosure & Disclaimer
  • Contact
  • Email Alerts
 

Website designed and developed by www.emperordesign.co.uk